5-year results of hypofractionated locoregional radiotherapy in early breast cancer HypoG-01 (UNICANCER): a French multicentre, randomised, non-inferiority, phase 3, open-label, controlled trial.

Date publication

mars 2026

Journal

Lancet (London, England)

Auteurs

Membres identifiés du Cancéropôle Est :
Dr CLAVIER Jean-Baptiste , Dr PEIGNAUX Karine

Tous les auteurs :
Rivera S, Ghodssighassemabadi R, Auzac G, Brion T, Kirova Y, Racadot S, Benchalal M, Clavier JB, Charra Brunaud C, Groulier A, Argo-Leignel D, Peignaux K, Benyoucef A, Pasquier D, Guilbert P, Goineau A, Tallet A, Bergeaud M, Lamrani-Ghaouti A, Michiels S,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/41794436

Résumé

Hypofractionated radiotherapy is standard for whole-breast radiotherapy, but 50 Gy in 25 fractions (5-week radiotherapy) is still standard in many countries when nodal radiotherapy is needed for morbidity concerns. The UNICANCER HypoG-01 trial aimed to assess morbidity and efficacy of hypofractionated locoregional radiotherapy delivering 40 Gy in 15 fractions (3-week radiotherapy) versus 5-week radiotherapy.

Mots clés

Humans, Female, Breast Neoplasms, radiotherapy, Middle Aged, France, Radiation Dose Hypofractionation, Aged, Adult, Treatment Outcome, Radiotherapy, Adjuvant, adverse effects

Référence

Lancet. 2026 03 7;407(10532):976-987